Results 81 to 90 of about 350,788 (241)

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

BAG2 Inhibits Cervical Cancer Progression by Modulating Type I Interferon Signaling through Stabilizing STING

Advanced Science, EarlyView.
Based on IP‐MS analysis, BAG2 is confirmed to be essential for ubiquitination and protein homeostasis regulation of STING in cervical cancer. BAG2 inhibits the ubiquitination and degradation of STING by forming a complex with STUB1, thereby activating the type I IFN signaling pathway and inhibiting the development of cervical cancer.
Shijie Yao, Siming Chen, Anjin Wang, Ziyan Liang, Xuelian Liu, Yang Gao, Hongbing Cai   +6 more
wiley   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

Advanced Science, EarlyView.
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng, Yunfang Yu, Wenjun Qiu, Qiyun Ou, Qianqian Mao, Luyang Jiang, Jianhua Wu, Jiani Wu, Huiyan Luo, Peng Luo, Wenchao Gu, Na Huang, Siting Zheng, Shaowei Li, Yonghong Lai, Xiatong Huang, Yiran Fang, Qiongzhi Zhao, Rui Zhou, Huiying Sun, Wei Zhang, Jianping Bin, Yulin Liao, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Min Shi, Wangjun Liao   +27 more
wiley   +1 more source

Chemotherapy adjuvant and chemotherapy-induced neutropenia

Taiwanese Journal of Obstetrics and Gynecology, 2022
Yiu-Tai Li, Szu-Ting Yang, Peng-Hui Wang
openaire   +3 more sources

KK2DP7 Stimulates CD11b+ Cell Populations in the Spleen to Elicit Trained Immunity for Anti‐Tumor Therapy

Advanced Science, EarlyView.
This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang, Lin Tang, Yusi Wang, Xuejing Zhou, Zhenyu Ding, Li Yang   +5 more
wiley   +1 more source

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

Advanced Science, EarlyView.
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu, Shenao Fu, Xi Zou, Hanjiang Zeng, Guangzu Cui, Yinghui Peng, Diya Tang, Fan Zhang, Hong Shen, Shan Zeng, Ying Han   +10 more
wiley   +1 more source

Engineered Genetic Circuits Activated by Bezafibrate Improve ESC‐Based TAA Cancer Vaccine Efficacy and PD‐L1 Nanobody Therapy

Advanced Science, EarlyView.
Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin, Shuzhen Liu, Mingshuo Zhan, Jian‐Dong Huang   +3 more
wiley   +1 more source

CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer

Advanced Science, EarlyView.
CCN1 modulates the tumor microenvironment in pancreatic cancer by promoting collagen‐dependent chemokine production, thereby facilitating immune evasion. Deletion of CCN1 not only suppresses tumor growth but also enhances immune cell infiltration and increases tumor sensitivity to both chemotherapy and immunotherapy.
Hongjie Fan, Huzi Zhao, Lili Gao, Yucheng Dong, Pei Zhang, Pengfei Yu, Yunfei Ji, Zhe‐Sheng Chen, Xinmiao Liang, Yang Chen   +9 more
wiley   +1 more source

Smart Organic–Inorganic Copolymer Nanoparticles Distinguish Between Microglia and Cancer Cells for Synergistic Immunotherapy in Glioma

Advanced Science, EarlyView.
The tumor microenvironment‐responsive nanoagonists are developed using an organic–inorganic copolymer composed of the polymer (PC6AB) and manganous phosphate ionic oligomers (MnP). PC6AB with membranolytic activity selectively interacts with tumor cell membranes to induce immunogenic cell death, while MnP activates the STING pathway in immune cells ...
Shiming Zhang, Kun Shang, Lidong Gong, Qian Xie, Jianfei Sun, Meng Xu, Xunbin Wei, Zhaoheng Xie, Xinyu Liu, Hao Tang, Zhengren Xu, Wei Wang, Haihua Xiao, Zhiqiang Lin, Hongbin Han   +14 more
wiley   +1 more source